Abstract
BackgroundMetastatic uveal melanoma(mUM), a rare cancer with poor prognosis, has a historical 1-yr overall survival (OS) rate of 52%. Tebentafusp, a bispecific (gp100 x CD3) ImmTAC, is approved for adult...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
